NCT06748287

A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

Completed EARLY_PHASE1 Last updated 27 December 2024

What this trial tests

EARLY_PHASE1 trial testing iGrow Hair Growth System in Alopecia in 104 participants. Completed in 1 February 2023.

Timeline

3 January 2017

Primary endpoint
1 February 2023

1 February 2023

Quick facts

Lead sponsor	University of Minnesota
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	104
Start date	3 January 2017
Primary completion	1 February 2023
Estimated completion	1 February 2023
Sites	1 location across United States

Drugs / interventions tested

• iGrow Hair Growth System
• Capillus352
• HairMax Ultima 12 Lasercomb
• HairMax Laserband 82

Conditions studied

• Alopecia — all drugs for Alopecia →

Sponsor

University of Minnesota

Who can join

Adults 21 to 85, any sex, with Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Photobiomodulation is a form of non-ionizing light therapy has been shown to stimulate cellular processes and reduce inflammation as well as improve pain and wound healing. Photobiomodulation has also been found to enhance fibroblast growth factor production. A challenge in clinic is to answer the patients' questions regarding which FDA-cleared device is the best to purchase. Therefore, this study was designed to gain experience with the use of the following devices and to clinically evaluate their efficacy: iGrow Hair Growth System, Capillus352, Hair Max Ultima 12 LaserComb, and HairMax Laserband 82. The purpose of this pilot research study is to clinically compare and evaluate FDA-cleared photobiomodulation devices after four months of treatment and one-month follow-up in subjects with alopecia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.